[New choice of therapy of pulmonary hypertension: endothelin receptor antagonist].
Shi
Gui-ying
GY
Department of Rheumatism, China PLA Hospital, Beijing 100853, China
D000328:Adult; D000077868:Atrasentan; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
D065128:Endothelin Receptor Antagonists; D010666:Phenylpropionates; D011743:Pyrimidines; D011759:Pyrrolidines; D013449:Sulfonamides; C107831:darusentan; D000077300:Bosentan; D000077868:Atrasentan